Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
3061-3080 of 3,900 trials

Crizotinib for Children with Severe Type 2 Neurofibromatosis

We are studying whether crizotinib can help reduce tumor size in children with severe type 2 neurofibromatosis who are not eligible for surgery or radiotherapy. We will also evaluate the safety of this treatment.

Neurofibromatosis Type 21-2 yearsEfficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesNeurologyOncology

Kidney Transplant in Children: Prolonged-Release Tacrolimus Study

We are studying a new form of tacrolimus for children who have undergone kidney transplantation. The goal is to see if it works as well and is as safe as the current version used.

Caucasian Pediatric Kidney Transplant Recipients1-2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesNephrologyPediatrics

Primary Sjögren's Disease: Efgartigimod Treatment Study

We are testing a new medication, efgartigimod, for adults with Primary Sjögren's Disease to see if it helps reduce disease activity and improve symptoms compared to a placebo.

Sjögren's Syndrome>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Gastroenteropancreatic and Thoracic Neuroendocrine Tumors: Cabozantinib and Lanreotide Study

We are studying the safety and effectiveness of a new combination treatment for patients with gastroenteropancreatic and thoracic neuroendocrine tumors. This trial aims to find out if this combination can improve treatment outcomes compared to current options.

Gastroenteropancreatic and Thoracic Neuroendocrine TumorEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesEndocrinologyOncology

Advanced Liver Cancer: BAY 3547926 Study

We are investigating the safety and effectiveness of a new drug, BAY 3547926, for people with advanced liver cancer. This study aims to understand how well it works in treating this condition.

Liver Cancer>2 yearsSafety phase (I)HepatologyOncology

Acromegaly: Debio 4126 Treatment Study

We are testing a new formulation of Debio 4126 in patients with acromegaly who have been treated with other medications. The study aims to see if it helps maintain normal hormone levels and evaluates its safety compared to a placebo.

Acromegaly1-2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementEndocrinology

Epstein-Barr Virus Diseases: Tabelecleucel Treatment

We are studying a new treatment called tabelecleucel for individuals with Epstein-Barr virus-associated diseases. The goal is to see if it can improve health outcomes compared to current options.

EBV-Related Lymphoproliferative Disorder>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesHematologyInfectious DiseasesOncology

Immune-Related Rheumatological Events in Cancer Patients

We are collecting data on how to better diagnose and manage joint and muscle issues caused by cancer treatments. This study involves multiple centers to improve care for patients receiving checkpoint inhibitors.

Cancer (all types)>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncologyRheumatology

Gastric Cancer: HLX22 Treatment Study

We are studying a new drug, HLX22, combined with standard treatments for patients with advanced gastric cancer. The goal is to see if it works better and is safe compared to existing treatment options.

Gastric Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesCost ReimbursementGastroenterologyOncology

Status Epilepticus Treatment in Elderly Patients

We are investigating a new treatment for established status epilepticus in older adults. This study aims to provide evidence on how effective this treatment is for this vulnerable population.

Status Epilepticus>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesNeurology

Stroke Care: HOPE Study on Blood Pressure Management

We are comparing standard blood pressure management to a personalized approach after mechanical thrombectomy for acute ischemic stroke patients. The goal is to see which method better supports recovery and brain health.

Acute Ischemic Stroke>2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesInternal MedicineNeurology

Cardiovascular Health in Type 2 Diabetes: COLCOT-T2D Study

We are studying whether colchicine and non-enteric coated aspirin can improve heart health in high-risk adults with type 2 diabetes. The goal is to see if these treatments can reduce serious heart-related events.

Unspecified Cardiovascular DiseaseConfirmation phase (III)6-10 visitsInvestigational MedicinesPartially RemoteCardiologyEndocrinology

Pain Medication Tapering for Persistent Spinal Pain

We are studying how different methods of reducing pain medication affect disability in patients with Persistent Spinal Pain Syndrome Type II after spinal cord stimulation. This research may help improve pain management strategies.

Persistent Spinal Pain Syndrome Type II1-2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteInternal MedicineNeurologyOrthopedics and Traumatology

Ovarian Cancer: NIraparib and Dostarlimab Study

We are testing a new treatment combination for patients with recurrent ovarian cancer who cannot have platinum therapy. The study aims to see if this combination helps patients live longer compared to standard chemotherapy.

Recurrent Ovarian CancerConfirmation phase (III)No PlaceboStandard MedicinesGynecology and ObstetricsOncology

Atherosclerotic Cardiovascular Disease: Maridebart Cafraglutide

We are studying whether maridebart cafraglutide can improve heart health in people with atherosclerotic cardiovascular disease who are overweight or obese. This trial compares its effects to a placebo alongside standard care.

Arteriosclerotic Cardiovascular DiseaseConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementCardiologyInternal Medicine

Maridebart Cafraglutide for Heart Failure and Obesity

We are studying whether maridebart cafraglutide can improve heart failure symptoms and reduce hospital visits for people with heart failure and obesity. This trial compares the new treatment to a placebo alongside standard care.

Heart FailureConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Melanoma Treatment: Vemurafenib, Cobimetinib, and Atezolizumab

We are studying a combination of three medications for patients with high-risk melanoma to see if it helps achieve a complete response. We also want to understand its effects on survival and safety.

High-Risk MelanomaEfficacy phase (II)No PlaceboStandard MedicinesDermatologyOncology

Buspirone for Weak Esophageal Motility

We are studying whether buspirone can improve swallowing and esophageal function in patients with poor motility. This trial compares the effects of buspirone to a placebo on symptoms and esophageal pressure measurements.

Ineffective Motility or Absent Peristalsis≤3 monthsMonitoring phase (IV)6-10 visitsStandard MedicinesPartially RemoteGastroenterology

ALS Treatment: Masitinib with Riluzole

We are studying whether adding masitinib to Riluzole helps improve outcomes for people with Amyotrophic Lateral Sclerosis. This trial will assess its safety and effectiveness compared to a placebo.

Amyotrophic Lateral Sclerosis6-12 monthsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesInternal MedicineNeurology

Multiple Sclerosis: Masitinib Treatment Study

We are investigating whether the oral medication masitinib is effective and safe for people with primary or secondary progressive multiple sclerosis without relapses. This study compares masitinib to a placebo to evaluate its impact on various symptoms and overall health.

Multiple Sclerosis1-2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesPartially RemoteNeurology